Edwin Rock - 14 Nov 2022 Form 4 Insider Report for GLYCOMIMETICS INC (GLYC)

Role
Chief Medical Officer
Signature
/s/ Brian F. Leaf, attorney-in-fact
Issuer symbol
GLYC
Transactions as of
14 Nov 2022
Net transactions value
+$309,000
Form type
4
Filing time
16 Nov 2022, 15:26:18 UTC
Previous filing
07 Sep 2022
Next filing
27 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GLYC Common Stock Purchase $143,000 +100,000 $1.43 100,000 14 Nov 2022 Direct F1
transaction GLYC Common Stock Purchase $166,000 +100,000 +100% $1.66 200,000 15 Nov 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.31 to $1.55 per share, with a weighted average purchase price of $1.43 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2 The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.52 to $1.75 per share, with a weighted average purchase price of $1.66 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.